Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
7/20/2010 • Vienna, Austria
For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance.
An update of current state of microbicide development will be provided. Speakers will provide a state of microbicide development update, safety and efficacy data from CAPRISA 004 and implications of the CAPRISA 004 trial results for the microbicide and PrEP field.
Presentations in This Session:
Introduction
Co-Chairs: Tim Farley (Switzerland)
Department of Reproductive Health and Research (WHO)
Gita Ramjee (South Africa)
Head – South Africa Medical Research Council’s HIV Prevention Research Unit
The Caprisa 004 Result in Context
Sheena McCormack (United Kingdom)
Clinical Epidemiologist, MRC Clinical Trials Unit
Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
Presented by Quarraisha Abdool Karim (South Africa)
Associate Professor of Clinical Epidemiology, Columbia University - Southern African Fogarty AIDS
Do Systemic and Genital Tract Tenofovir Concentrations Predict HIV Seroconversion in the CAPRISA 004 Tenofovir Gel Trial?
Presented by Angela DM Kashuba (United States)
Associate Professor of Pharmacy at the University of North Carolina-Chapel Hill (UNC)
Safety of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
Presented by Salim Abdool Karim (South Africa)
Chair, Department of Reproductive Health & Research WHO, Geneva
Director, Centre for the AIDS Programme of Research in South Africa (Caprisa), Durban
Director, HIV Prevention & Vaccine Research Unit, MRC
Pro Vice-Chancellor (Research), University of KwaZulu-Natal, Durban
Contextualising the CAPRISA 004 Trial Results in the HIV Prevention Field
Presented by Aaron Motsoaledi (South Africa)
Minister of Health
